HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gabay, M. Search for Related Content PubMed PubMed Citation Articles by Gabay, M.

MICHAEL GABAY, PHARM.D., BCPS, is Clinical Assistant Professor, College of Pharmacy, University of Illinois Medical Center at Chicago, 833 South Wood Street, M/C 886, Chicago, IL 60612 (mgabay{at}uic.edu).

Address correspondence to Mary Ellen Bonk, Pharm.D., University HealthSystem Consortium, 2001 Spring Road, Suite 700, Oak Brook, IL 60523-1890 (bonk{at}uhc.edu).

Purpose. The pharmacology, clinical efficacy, adverse effects and toxicities, drug interactions, dosage and administration, and safety issues related to the use of absorbable hemostatic agents are reviewed. Summary. Absorbable hemostatic agents exert their pharmacologic effects at various points within the coagulation cascade. These agents are indicated for use during surgical procedures as adjunctive therapy when bleeding is not controlled by conventional methods. Early clinical data on absorbable hemostatic agents revealed a beneficial effect with regard to controlling capillary bleeding, achieving hemostasis during vascular surgery, and controlling bleeding from fistula-puncture sites. Few randomized controlled clinical trials have directly compared available agents, but case reports describing the efficacy of absorbable hemostatic agents in specific situations, especially unlabeled uses of thrombin, abound. Existing trials have compared the efficacy of established agents with newer agents, including fibrin sealants, with varying results. A variety of rarely occurring adverse effects have been reported with the administration of absorbable hemostatic agents; some of these rare effects, such as paralysis, are quite severe. No standardized dosing regimens are available for these agents, although surgeons may have a preference for a particular regimen based on their own clinical experience. No drug interactions involving absorbable hemostatic agents have been published; however, the use of these agents with other medications that affect hemostasis may disrupt clot formation. Conclusion. Absorbable hemostatic agents are useful as adjunctive therapy during surgical procedures when conventional methods do not control bleeding. Although rare adverse effects have occurred with these agents, their careful administration will prevent serious adverse outcomes. Index terms: Dosage; Drug administration; Drug interactions; Fibrin; Hemostatics; Surgery; Thrombin; Toxicity

 

This article has been cited by other articles:

				S. Krishnan, T. M. Conner, R. Leslie, S. Stemkowski, and A. Shander Choice of Hemostatic Agent and Hospital Length of Stay in Cardiovascular Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2009; 13(4): 225 - 230. [Abstract] [PDF]

				M. B. Ferschl and M. D. Rollins Thromboemboli, Acute Right Heart Failure and Disseminated Intravascular Coagulation After Intraoperative Application of a Topical Hemostatic Matrix Anesth. Analg., February 1, 2009; 108(2): 434 - 436. [Abstract] [Full Text] [PDF]

				A. Terrab, D. Pawlak, P. Spaay, D. Hoppensteadt, and J. Fareed Further Removal of Factor V Related Antigen From Bovine Thrombin by Utilizing a Membrane-Filtration Step Clinical and Applied Thrombosis/Hemostasis, April 1, 2008; 14(2): 135 - 140. [Abstract] [PDF]